Post a Comment Print Share on Facebook
Featured Newsteam Ercan DEL (Deutsche Eishockey Liga) Aorta Ruhrgebiet

Novartis, with more turnover and less profit

Novartis is grown in the first quarter, thanks to its Pharma division. The Pharma has benefited the group, particularly to the good development of the growth d

- 175 reads.

Novartis, with more turnover and less profit

Novartis is grown in the first quarter, thanks to its Pharma division. The Pharma has benefited the group, particularly to the good development of the growth drivers. For the further course of business, Novartis provides a higher gain in prospect.

net sales for the first three months of 2019, according to the message from Wednesday at 11.1 billion Swiss francs. This is a Plus of 2 percent compared to the same period last year. The cleaved eye is Alcon division have already been factored out. The Figures relate only to continuing operations. Novartis had adopted at the beginning of April with an IPO of the business. Of Alcon, sales were 1.78 billion dollars, the previous year's level.

Sandoz 2.3 billion in sales in the first quarter

The largest revenue contribution but as usual, the Pharma sector of Innovative Medicines. The division increased its revenues in the first quarter by 5 percent to $ 8.8 billion. The division has benefited from continuing good demand for the drug Cosentyx and Entresto.

The generic drugs division Sandoz has implemented in the first three months of 2.3 billion. The are 8 percent less than in the first quarter of 2018. Here, the price pressure on the American made market will continue to have a negative impact, it was said in the message. The operating profit fell by 5 percent to 2.2 billion dollars. The net profit also fell by 5 percent to 1.9 billion dollars.

growth in the high single-digit percentage range

With the publication of the Figures for the first quarter, Novartis increased the full-year Outlook for the group's operating profit. New growth in the high single-digit percentage range is expected at constant exchange rates. So far, the Management is expecting an increase in the mid single-digit percentage range. The revenue is further projected to increase in the mid single-digit percentage range.

The sales forecasts for the two divisions Innovative Medicines (increase in the mid single-digit percentage range) and Sandoz (sales, largely at the previous year's level) wur1den confirmed.

For the generics division, Sandoz, is called Richard Saynor to the new boss. He occurs to be at the office no later than 1. August 2019. Saynor comes from a competitor, GSK. He has more than 20 years of leadership experience worldwide in the area of generics, as well as for established pharmaceutical brands, wrote to Novartis.

(sda)

Created: 24.04.2019, 07:13 PM

Avatar
Your Name
Post a Comment
Characters Left:
Your comment has been forwarded to the administrator for approval.×
Warning! Will constitute a criminal offense, illegal, threatening, offensive, insulting and swearing, derogatory, defamatory, vulgar, pornographic, indecent, personality rights, damaging or similar nature in the nature of all kinds of financial content, legal, criminal and administrative responsibility for the content of the sender member / members are belong.